Shares of CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY – Get Free Report) fell 1% during mid-day trading on Tuesday . The company traded as low as $49.74 and last traded at $50.04. 8,623 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 23,599 shares. The stock had previously closed at $50.5486.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the stock. Zacks Research upgraded shares of CochLear from a “strong sell” rating to a “hold” rating in a report on Monday, June 22nd. Canaccord Genuity Group downgraded CochLear from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 18th. Jefferies Financial Group lowered CochLear from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Royal Bank Of Canada cut CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 price objective for the company. in a report on Thursday, July 16th. Six analysts have rated the stock with a Hold rating, Based on data from MarketBeat, CochLear currently has a consensus rating of “Hold” and a consensus price target of $117.00.
Get Our Latest Stock Analysis on CochLear
CochLear Trading Down 1.0%
About CochLear
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Recommended Stories
- Five stocks we like better than CochLear
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
